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Abstract
Pathogenic Escherichia coli strains cause a wide variety of intestinal and extraintestinal infections. The widespread geographical clonal
dissemination of intestinal pathogenic E. coli strains, such as E. coli O157:H7, is well recognized, and its spread is most often attributed to
contaminated food products. On the other hand, the clonal dissemination of extraintestinal pathogenic E. coli (ExPEC) strains is also
recognized, but the mechanism of their spread is not well explained. Here, I describe major pandemic clonal lineages of ExPEC based on
multilocus sequence typing (MLST), and discuss possible reasons for their global dissemination. These lineages include sequence type (ST)
131, ST393, ST69, ST95, and ST73, which are all associated with both community-onset and healthcare-associated infections, in particular
urinary tract infections and bloodstream infections. As with many other types of drug-resistant Gram-negative and Gram-positive bacterial
infections, drug-resistant ExPEC infections are recognized to be caused by a limited set of clonal lineages. However, reported observations
on these major pandemic lineages suggest that the resistance phenotype is not necessarily the determinant of their clonal dissemination.
Both epidemiological factors and their intrinsic biological ‘ﬁtness’ are likely to contribute. An important public health and clinical concern is
that pandemicity itself may be a determinant of progressive drug resistance acquisition by clonal lineages. New research is urgently needed
to better understand the epidemiological and biological causes of ExPEC pandemicity.
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Introduction
Escherichia coli represents a diverse collection of Gram-nega-
tive bacterial organisms that occur as pathogens and as
mammalian intestinal commensals. Intestinal pathogenic E. coli
strains are generally divided into those that cause diarrhoea by:
(i) expressing heat-labile or heat-stable toxin (enterotoxigenic
E. coli (ETEC)) or Shiga toxin (Shiga toxin-producing E. coli
(STEC), including enterohemorrhagic E. coli (EHEC)); (ii)
invading the intestinal mucosa (enteroinvasive E. coli (EIEC));
(iii) causing attaching and effacing lesions in the intestinal
mucosa (enteropathogenic E. coli (EPEC)); and (iv) other less
well-deﬁned mechanisms (e.g. enteroaggregative E. coli (Eag-
gEC)) [1]. Whereas ETEC, EIEC, EPEC, and EaggEC remain
important causes of diarrhoea among children in developing
countries, the most prevalent intestinal pathogenic E. coli
strains in developed countries are STEC/EHEC. The most
common EHEC, E. coli O157:H7, is usually commu-
nity-acquired via contaminated food or water. A newly
recognized clonal lineage belonging to serotype O104:H4 that
carries virulence traits of both EHEC and EaggEC was
responsible for a massive outbreak of bloody diarrhoea,
haemolytic–uraemic syndrome and death in Germany in 2011
that was traced to contaminated bean sprouts [2,3].
Widespread geographical clonal dissemination of intestinal
pathogenic E. coli is frequently detected, primarily because these
organisms cause outbreaks of diarrhoea, which can be readily
investigated. These investigations often implicate food products
that enter domestic and global food distribution networks.
As an extraintestinal pathogen, E. coli is the most common
cause of community-acquired urinary tract infections (UTIs)
and the most common Gram-negative bacterium associated
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with bloodstream infections (BSIs) in both developed and
developing countries. Community-onset UTIs or health-
care-associated BSIs caused by extraintestinal pathogenic
E. coli (ExPEC) are not often recognized to occur as an
outbreak or an epidemic. However, ExPEC strains belonging
to related lineages are distributed locally, regionally, and
globally. The mechanism of clonal dissemination of ExPEC is
not obvious. This review will describe the major pandemic
clonal groups of ExPEC responsible for community-onset and
healthcare-associated infections, and discuss possible reasons
for their dissemination.
Deﬁnitions
‘Clone’ is often used to describe an organism descending from
a common precursor strain by non-sexual reproduction, with
phenotypic or genotypic traits characterized by a strain typing
method showing it to belong to the same group. In this review,
the term ‘E. coli clone’ will be used to refer to a set of E. coli
strains that share an indistinguishable genotypic characteristic
based on a method used to genotype them. According to such
a deﬁnition, the most precise way to characterize clones
would be to perform whole genome sequencing, which is
increasingly being applied to study infectious disease transmis-
sion. Short of whole genome sequencing, however, multilocus
sequence typing (MLST) is one highly reproducible method
that is commonly applied to genotype E. coli. With this
genotyping method, E. coli strains are assigned a sequence
type (ST) with a numerical designation, according to two
widely used and standardized schemes (http://mlst.warwick.ac.
uk; http://www.pasteur.fr/recherche/genopole/PF8/mlst/EColi.
html; Achtman and Pasteur, respectively) [4,5].
Although MLST is useful for demonstrating phylogenetic
relationships of a large collection of bacterial lineages, it does
not have the discriminatory power to show genetic changes in
strains during transmissions that occur over a short time
period (e.g. outbreaks). A more discriminating test is
pulsed-ﬁeld gel electrophoresis (PFGE), which is another
widely used method for genotyping E. coli. PFGE forms the
basis for national and international surveillance systems, such
as the PulseNet in the USA and PulseNet International (http://
www.cdc.gov/pulsenet/; http://www.cdc.gov/globalhealth/pro
grams/pulsenet.htm). PFGE is often used to trace contami-
nated food products during outbreaks or epidemics.
Because PFGE is more discriminating than MLST, if it is used
ﬁrst to genotype a collection of E. coli isolates from sources not
recognized to be outbreaks or epidemiologically related, their
phylogenetic relationships could be missed. This review will
apply the MLST deﬁnition to describe E. coli strains as clones or
clonal groups in discussing their geographical dissemination or
phylogenetic relationships. Their PFGE patterns (pulsotypes)
will be described in discussing their modes of transmission.
Selected Pandemic ExPEC Lineages
E. coli that causes extraintestinal infections was ﬁrst called
ExPEC by Johnson and Russo in 2002 [6]. An assignment of
E. coli isolates to ExPEC status based on a set of virulence
genes was proposed by Johnson et al. [7]. Here, published
studies that used MLST to genotype ExPEC isolates obtained
from consecutively collected, non-duplicate clinical samples
not selected by drug resistance were ﬁrst reviewed (Table 1)
[8–16]. The predominant clonal ExPEC groups (ST131, ST69,
ST95, and ST73) described in eight or more of these reports
were then selected for this review. For historical reasons,
ST393 is also discussed. No other typing methods allow
comparison of such a large number of reports, and hence they
are not discussed in this review.
ST393 E. coli O15:K52:H1
During 1986 and 1987, a community-wide outbreak of
infections caused by multidrug-resistant E. coli serotype O15:
TABLE 1. Multilocus sequence type analysis of non-duplicate Escherichia coli isolates obtained from population-based surveys or
consecutively collected clinical samples, 1997–2012
Place (number of isolates) Year Type of study Samples
Predominant ST clonal
groups founda References
San Francisco, USA (246) 2007–2010 Hospital Blood 131, 95, 73, 69, 12, 10, 405, 38 Adams-Sapper et al. [8]
Manchester, Preston, UK (300) 2007, 2009 Hospital Urine 73, 131, 69, 95, 10, 127 Gibreel et al. [9]
North-western England (88) 2004–2005 Clinical laboratories Urine, blood 131, 73, 95, 69, 410, 416, 155, 391 Lau et al. [10]
Montreal, Canada (256) 2006 Outpatient clinic Urine 69, 131, 95, 73 Manges et al. [11]
Nottingham, UK (121) 2008–2009 Hospital Urine 131, 73, 69, 95 Croxall et al. [12]
Yorkshire, Humber, UK (770) 2010–2012 Clinical laboratories Blood 73, 131, 69, 95, 12, 404, 10, 127, 141 Horner et al. [13]
Different regions, Spain (500) 2009 Five hospitals All specimen types 131, 69, 393 Blanco et al. [14]
Paris, France (304) 2008–2009 Ten hospitals All specimen types 131, 10, 73 Brisse et al. [15]
Clichy, France (110) 1997–2006 Hospital Blood, ascites 95, 73, 14, 10, 23, 131, 69 Bert et al. [16]
ST, sequence type.
aCluster of strains recovered from two or more independent patients per clonal group (from highest to lowest frequency, left to right).
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K52:H1 was recognized in south London [17]. This was one of
the ﬁrst recognized community-setting outbreaks of ExPEC
infections, which mostly included UTI, but also cases of BSI,
meningitis, and endocarditis. During the same period, several
hospitals in London reported an increased prevalence of
bacteraemia caused by serogroup O15 [18–20]. Prior to this
period, serotype O15:K52:H1 was uncommon in London.
Subsequently, serotype O15:K52:H1 has been isolated from
hospital and community-onset infections in Denmark, Spain,
other western European countries, and several states in the
USA [21–27].
Prior to genotyping by MLST, serotype O15:K52:H1 strains
were described as belonging to a clonal group on the basis of
their serotype and E. coli Reference (ECOR) phylogenetic
group membership (group D), shared drug susceptibility
pattern, O15:K52:H1-speciﬁc fumC single-nucleotide polymor-
phism [28], and a consensus virulence factor (VF) proﬁle,
shown in Table 2 [25]. By MLST, these strains belong to
ST393, a member of the ST31 complex [25].
ST393 was reported from Korea in 2006–2007 [29]. In a
national survey, ST393 strains expressing CTX-M-type
extended-spectrum b-lactamase (ESBL), along with two other
STs (ST131 and ST69), were found to constitute 30% of
multidrug-resistant ExPEC isolates from ﬁve hospitals in
different regions of Spain over a 1-month period in 2009
[14]. ST393 was one of ﬁve most common ESBL-producing STs
among 654 ESBL-producing ExPEC isolates from four hospitals
in north-western Spain from 2005 to 2008 [30]. In an 11-year
study in Canada, ST393 was one of seven major ExPEC STs in
the late 2000s [31]. Thus, ST393 continues to spread
geographically, and remains a predominant ExPEC clonal
group in parts of Europe.
An analysis of 100 archived international serotype O15:
K52:H1 strains isolated from 100 distinct human sources from
1975 to 2006 for resistance and virulence genes has shown
that this ExPEC clonal group progressively gained resistance
over this 30-year period, while stably maintaining its virulence
gene proﬁles [25]; the resistance score increased by an average
of 2.8 antimicrobial drugs every 10 years.
The sudden appearance in London of serotype O15:K52:H1
in the late 1980s and its subsequent spread elsewhere are not
explained. This clonal group’s ﬁrst recognition most likely
occurred because the strains were multidrug-resistant. That is,
drug-resistant strains are more likely to be cultured, tested,
and stored in clinical laboratories, and hence be analysed
further. Population-based, rather than convenience, samples
have revealed non-resistant strains of serotype O15:K52:H1
[25]. In a collection of 100 serotype O15:K52:[H1] isolates
obtained from the International Escherichia and Klebsiella
Centre (WHO) (the bracket indicates motile and non-motile
strains of serotype O15:K52), 45% were susceptible to 13
drugs tested [25]. As will be described below, a large
proportion of drug-resistant community-acquired or health-
care-associated UTIs and BSIs are caused by ExPEC strains
belonging to a small set of clonal groups, even when selective
pressures from drugs potentially exist for all strains. Thus, one
question that this review will address is whether the multidrug
resistance phenotype of an ExPEC strain determines its clonal
expansion and prevalence.
E. coli ST131
In the mid-2000s, PFGE analyses of E. coli isolates producing
ESBL CTX-M-15 in the UK and Canada identiﬁed a pulsotype
cluster with >80% similarity, designated clone A in the UK and
clone 15A in Canada [32,33]. Because these PFGE patterns did
not satisfy the criteria for relatedness outlined by Tenover et al.
[34], these strains were initially not recognized to belong to a
related lineage. Subsequent genotyping by MLST identiﬁed them
as belonging to the same lineage, i.e. ST131 complex [5,35],
which is a member of phylogenetic group B2 and sero-
type O25b:H4. More recently, variants of ST131 belonging to
serotypes O16:H5 and NT:H4 have been reported from
TABLE 2. Phenotypic and genotypic characteristics of pandemic extraintestinal pathogenic Escherichia coli clonal lineages
MLST Serogroups, serotypes
ECOR
phylogenetic
group Prototypic virulence factor genes References
ST393 O15b:K52:H1 D iha (adhesin-siderophore), ﬁmH (type 1 ﬁmbriae), fyuA (yersiniabactin receptor),
iutA (aerobactin receptor), and kpsM II (group 2 capsule)
[25]
ST131 O25b:H4, O16:H5, NT:H4, O157 B2 iha and ﬁmH (adhesins), sat (toxin), fyuA/irp2 and iutA/iucD (siderophore systems),
kpsM II, usp (uropathogenic speciﬁc protein), traT (serum resistance-associated),
ompT (outer membrane protease), and malX (pathogenicity island marker)
[36,37,39,42]
ST69 O11, O15, O17, O44, O73,
O77, O86, O125ab, O25b
D F10 and F16 papA alleles, papG allele II, sfa/focDE (S and F1C ﬁmbriae), focG
(F1C ﬁmbriae adhesin), iha, hlyD, cnf1, fyuA, iutA, iroN, malX, and afa/dra
(Dr antigen-binding adhesins), cdtB, and K1 kpsMT
[59,60]
ST95 O1:K1:H7, O2:K1:H7, O18:K1:H7,
O45:K1:H7
B2 ﬁmH, ﬁmAvMT78, papG II, iucD, iroN, kpsM II-K1, cvaC, iss, traT, malX, usp, and tsh [11,16,71]
ST73 O6:H B2 papC, papEF, papG, sfa/foc, ﬁmH, hra, hlyA, cnf1, pic, vat, iroN, fyuA, kpsM II, usp, and ompT [16,76]
ECOR, Escherichia coli Reference; MLST, multilocus sequence typing; ST, sequence type.
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Europe, Japan, and South Asia [36–38]. One study from
Australia found an ST131 strain belonging to serogroup O157
[39]. The prototypic ST131 VF proﬁle is shown in Table 2. Many
excellent reviews have been published on the microbiological,
epidemiological and clinical characteristics of infections caused
by ST131, which is currently the most frequently studied of the
pandemic ExPEC clonal lineages [5,35,40–45].
Worldwide, a substantial proportion of the increase in
drug-resistant ExPEC infections, especially those caused by
strains resistant to extended spectrum b-lactams and ﬂuor-
oquinolones, can be attributed to the spread of this single
lineage. Most reports describe ST131 strains that typically
produce CTX-M-type ESBLs, especially CTX-M-15, encoded
by blaCTX-M-15 on a plasmid; they are usually resistant to
ﬂuoroquinolones, owing to chromosomal gene mutations (gyrA
and parC) [5,26,46]. The types of CTX-M ESBL gene carried by
ST131 can vary geographically, however [31,36–38,47–50].
The reported frequency of drug resistance and resistance
proﬁles among ST131 strains depends on the study design—
population vs. sample surveys, hospital vs. community-based
studies, and sources of the isolates (blood, urine, wound,
cerebrospinal ﬂuid, and stools). ST131 isolates identiﬁed in
faecal samples of 332 healthy volunteer subjects in Paris did
not express any CTX-M ESBL [51].
The origin of ST131 is unknown. A retrospective analysis of
ESBL-producing E. coli isolates from the Calgary Health Region
in Canada from 2000 to 2007 identiﬁed ST131 as early as 2003
[52], and in France it was identiﬁed as early as 1994 [53]
(Table 3). In a 2007 SENTRY and MYSTIC study, a reference
strain used for virulence proﬁle typing was a ﬂuoroquino-
lone-susceptible ST131 strain (H15) isolated in 1985 [42].
ST131 strains are commonly isolated from both healthcare and
community-associated infections, but whether they originate in
the community or healthcare setting is not well established. In
a study at a general public hospital in San Francisco, ST131
accounted for 23% of 239 E. coli BSI isolates consecutively
collected from July 2007 to September 2010 [8]. Analysis by
time of the ﬁrst blood culture collection (<48 h vs. >48 h)
revealed that >70% of the cultures grew E. coli within <48 h of
admission, suggesting that most of these infections were
acquired prior to hospitalization [8]. Although these commu-
nity-onset infections could, nevertheless, have had a healthcare
association, it is clear that ST131 is now a pandemic clonal
lineage, and is responsible for a large proportion of drug-resis-
tant ExPEC infections in a variety of clinical settings.
ST69 complex (clonal group A (CgA))
From October 1999 to January 2000, 255 E. coli isolates from
consecutive urine samples from 228 women with uncompli-
cated community-acquired UTIs were analysed at a public
university campus in northern California [54]. Of 55 isolates
found to be resistant to trimethoprim–sulphamethoxazole, 28
(51%) shared an identical gel electrophoretic banding pattern
based on ERIC2-PCR typing [55], which was described as CgA
[54]. By MLST, CgA strains were subsequently found to belong
to the ST69 complex [56]. ST69 strains belong to ECOR
phylogenetic group D and serogroups that include O11, O15,
O17, O44, O73, O77, O86, O125ab, and O25b [11,14,56–58].
The prototype ST69 strain (O11; ATCC BAA-457) has the VF
proﬁle shown in Table 2 [59,60].
Since the ﬁrst recognition in 1999, CgA and ST69 strains
have been reported from many other regions of the world
from both community-acquired and healthcare-associated
UTIs and BSIs [8,57,61–65]. Most strains are multidrug-resis-
tant, and typically harbour a single arrangement of a gene
cassette (dfrA17–aadA5) encoding dihydrofolate reductase and
aminoglycoside adenyltransferase, respectively, on a class I
integron [66,67]. ST69 strains expressing ESBL are currently
not common. Thus, if a study selects ExPEC isolates on the
basis of extended-spectrum cephalosporin resistance, ST69
may be missed or under-represented in such a study sample.
Population-based prospective follow-up studies at the
above-mentioned California community found that CgA and
other clonal groups of ExPEC causing UTI ﬂuctuate over time.
A 1-year follow-up study showed that the prevalence of CgA
declined by 38%, but that the prevalence of trimethoprim–
TABLE 3. Non-human sources of pandemic extraintestinal pathogenic Escherichia coli clonal groups and the year of their ﬁrst
isolation recorded in the multilocus sequence typing (MLST) database
MLST
Food and food
animal source
Companion and
wild animal
Year and source of ﬁrst
isolate in MLST databasea References
ST393 Unreported Dog 2001, BSI [27]
ST131 Poultry, swine, cattle Dogs, cats, horse,
seagull, urban rat
1992, poultry
2001, human UTI
[39,93–96,98,99,101–105]
ST69 or CgA Cow, pork, poultry Seagull 1999, human UTI [96,97,102,106]
ST95 Poultry, honeydew melon, Wild birds, dog 1941, human UTI [71,96,100]
ST73 Unreported Dogs, cats 1917, unknown [77]
BSI, bloodstream infection; UTI, urinary tract infection.
aAchtman scheme: http://mlst.warwick.ac.uk.
ª2014 The Author
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 380–390
CMI Riley Pathogenic Escherichia coli 383
sulphamethoxazole resistance remained the same [68]. Six
other clonal groups as deﬁned by ERIC2-PCR typing were
identiﬁed and found to be responsible for 32% of trimetho-
prim–sulphamethoxazole-resistant UTIs. Another study in the
same community analysed 780 E. coli isolates from women
with UTIs in October–January in 1999–2000, 2000–2001,
2003–2004, and 2004–2005 [69]. The prevalence of trimeth-
oprim–sulphamethoxazole resistance showed no trend over
this period, but only four clonal groups, including CgA,
accounted for more than half of the trimethoprim–sulpha-
methoxazole-resistant UTIs [69]. In a hospital-based study in
San Francisco of E. coli BSI isolates consecutively collected
from 2007 to 2010, ST69 complex was the fourth most
common ExPEC ST (after ST131, ST95, and ST73) [8]. ST69
was recovered from a blood culture obtained <48 h after
admission in 83% of all cases, as compared with 73% for ST131.
These studies suggest that ST69 is a clonal ExPEC group
circulating predominantly in the community as opposed to
healthcare settings.
ST95 complex
ST95 ExPEC strains belong to phylogenetic group B2, and
serotypes O1:K1:H7, O2:K1:H7, and O18:K1:H7 [70]. A
typical VF proﬁle is shown in Table 2 [71]. K1 capsule-bearing
serotypes, including those belonging to ST95, are also tradi-
tionally associated with neonatal meningitis [72,73]. ST95
strains include avian pathogenic E. coli strains that cause
colibacillosis in domestic and wild birds [74,75]. In the San
Francisco study described above, ST95 was the second most
common clonal ExPEC group isolated from patients with BSI.
In a hospital in Clichy, France, it was the most common clonal
group among E. coli isolates obtained between 1997 and 2006
from blood and ascitic ﬂuid [16].
One distinct feature of this clonal lineage is the relative low
frequency of multidrug resistance—more than half of 40 ST95
isolates from the San Francisco hospital study were susceptible
to all drugs tested, whereas all 51 ST131 isolates in the same
study were resistant to at least one drug [8]. Interestingly, a
more recent (2010) ST95 BSI isolate from this same study was
found to carry blaCTX-M and blaKPC genes [8]. In Montreal, only
one of four ST95 isolates from patients with UTIs was resistant
to any drug, and, between 2007 and 2009, uropathogenic ST95
isolates from laboratories across north-western England had
the lowest resistance score among the nine commonest ST
clonal groups [9,11]. These observations may lead to a
suggestion that the ST95 clonal lineage is a recently introduced
pandemic strain that is still undergoing drug resistance
selection. However, the earliest isolation of this strain
recorded in the MLST database occurred in 1941 (Table 3).
This, and the observation made with ST393 above [25],
nevertheless highlight the point that drug resistance phenotype
itself is not a major determinant of clonal dissemination of an
ExPEC organism.
ST73 E. coli O6:H1
ST73 strains belong to ECOR phylogroup B2 and sero-
type O6:H1 [76,77]. It was the most common ST among the
major clonal ExPEC groups from urine and blood in two
studies in the UK from the late 2000s [9,13] (Table 1). It was
the third most common ST causing BSI among patients
admitted to a hospital in San Francisco and in ten different
hospitals in Paris, France [8,15]. It has also been reported to be
one of the predominant ExPEC types expressing CTX-M-15
ESBL from Cairo, Egypt [78]. It is isolated from health-
care-associated and community-associated or commu-
nity-onset infections. ST73 strains with closely related PFGE
types have been isolated from humans, dogs, and cats,
suggesting cross-species transmission of this genotype [77].
Incidentally, the prototypic pyelonephritogenic strain CFT073,
ﬁrst isolated from the blood of a woman with pyelonephritis
[79], and that is often used as a reference strain in animal
model studies, belongs to ST73 [77]. The characteristic VF
proﬁle genes are shown in Table 2 [76].
Other clonal ExPEC lineages
Table 1 shows other clonal ExPEC strains identiﬁed among the
predominant ExPEC clonal groups in more than one region—
ST10, ST12, and ST127. Genotyping studies of selected isolates
based on resistance to extended-spectrum cephalosporins or
ﬂuoroquinolones have identiﬁed predominant clonal groups
that appear to be more restricted geographically. For example,
ST38 (O86:H18) was found to be the most common clonal
group among ESBL-producing ExPEC isolates in Japan in a
survey of 37 hospitals between 2002 and 2003 [80]. In the UK,
among ESBL-negative but ciproﬂoxacin-resistant bloodstream
isolates from a survey conducted in 2001–2002, the most
common ST was ST405 [81]. These studies demonstrate that
there are other clonal ST groups that are perhaps threatening
to become pandemic strains. What drives them to cause a
pandemic is unknown. Potential mechanisms are discussed
below.
Role of Drug Resistance in ExPEC Clonal
Dissemination
One would expect antimicrobial drug use in healthcare settings
in different regions of the world to exert selective pressures
on a wide variety of ExPEC lineages, and hence we should
observe many drug-resistant genotypes. However, studies
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everywhere based on population-based surveys or consecu-
tively collected samples show that a limited set of E. coli
genotypes account for a large proportion of multidrug-resis-
tant strains. Such geographical dissemination and predomi-
nance of bacterial lineages is not limited to E. coli species. This
phenomenon appears to be a general feature of other
drug-resistant Gram-negative and Gram-positive bacteria.
However, recent observations made with ST95 suggest that
this dissemination is not likely to be related to drug resistance
as such, as a large proportion of the ST95 and ST393 isolates
appear to be susceptible to all drugs tested. That is,
drug-susceptible strains can also cause pandemics. Mechanisms
of clonal dissemination could therefore include biological
characteristics unrelated to drug resistance (Fig. 1).
Biological Factors that May Facilitate Clonal
Expansion
For intestinal E. coli pathogens, such as ETEC, EPEC, EIEC, and
STEC/EHEC, the ability to cause diarrhoea can be speciﬁcally
attributed to distinct virulence determinants that deﬁne them
as belonging to these groups of intestinal pathogens [1]. With
ExPEC, such characterizations are not as straightforward. In
the past, pathogenic E. coli strains were placed in ECOR
phylogenetic group B2 and, to a lesser extent, in group D,
whereas commensal E. coli strains were placed in group A
[82–84]. We know today that group D strains (e.g. ST69,
ST393, and ST405) are common ExPEC lineages globally.
In the 2000s, Johnson et al. [6,85–87] proposed a VF proﬁle
typing method based on PCR-based analysis of key genes
associated with recognized virulence phenotypes such as
mucosal colonization, iron acquisition, cytotoxins, and poly-
saccharide capsules, as well as a marker of a pathogenicity
island (Table 2). A VF proﬁle analysis comparing ST131 and
non-ST131 strains has shown that ST131 strains in different
regions of the world possess higher virulence scores (number
of distinct virulence markers/ST) and a set of genes that are
signiﬁcantly more frequent in ST131 than in non-ST strains
[14,42,88]. A Canadian study compared ST131 with other
pandemic clonal lineages (ST393 and ST69) from cases of UTI
from 2002 to 2004, and did not ﬁnd a signiﬁcant difference in
Biological determinants of ExPEC 
‘fitness’ in a competitive niche
Selection by antimicrobial drugs 
in healthcare settings
Selection by antimicrobial drugs 
in food animal husbandry
Dissemination by contaminated 
food products
Dissemination by ‘medical tourism’ 
and other human activities
FIG. 1. Factors that may drive the pandemic spread of extraintestinal pathogenic Escherichia coli (ExPEC).
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overall virulence scores; however, it found signiﬁcant differ-
ences in some of the markers possessed by ST131 strains [61].
As ST393 and ST69 are also globally spread, these gene
differences are not likely to be responsible for their dissem-
ination. To date, no set of so-called VF genes has been clearly
shown to be linked to clonal dissemination of any ExPEC
lineage. Virulence is not necessarily connected with transmis-
sibility.
It is possible that these pandemic lineages possess other
biological factors that provide them with increased ‘ﬁtness’,
giving them a competitive advantage over other ExPEC or
non-pathogenic E. coli lineages that reside in the same niche
(Fig. 1). These factors may allow them to outcompete other
strains and become the predominant bacterial population in
that niche, from which they spread, the spread being facilitated
by antimicrobial drug selective pressures in healthcare settings
or food animal husbandry (where they acquire drug resis-
tance), other human activities, or contaminated vehicles. Thus,
their biological ‘ﬁtness’ itself may be a ‘risk factor’ for such
lineages to eventually acquire drug resistance (Fig. 1).
Animal model experiments
Mouse models of ascending UTI and sepsis are often used to
compare the virulence potential of E. coli strains [89–91]. In a
murine subcutaneous sepsis model, Johnson et al. [89] tested
ST131 and non-ST131 isolates that were susceptible and
resistant to ﬂuoroquinolones, and found no difference in the
severity of illness caused by these different strains. However,
pap (P ﬁmbriae), vat (vacuolating toxin), kpsM II (group 2
capsule), ibeA (invasion of brain endothelium) and clbB/N
(colibactin synthesis) in any ExPEC ST strains were signiﬁcantly
associated with virulence [89]. At least according to the mouse
model, there is no evidence that ST131 strains are any more
virulent than other ExPEC strains, and this mouse virulence
phenotype cannot explain its global dissemination. It should be
noted that most E. coli isolates obtained from human subjects
with UTI or BSI symptoms are, by deﬁnition, virulent. Hence,
virulence assays are not likely to provide meaningful clues
regarding the disseminative capacity of ExPEC lineages.
Epidemiological Factors that Facilitate Clonal
Expansion
The recognized VFs of intestinal pathogenic E. coli organisms
do not facilitate their clonal distribution. The geographical
spread of common intestinal pathogenic E. coli strains, such as
those belonging to EHEC serotype O157:H7, is largely med-
iated by contaminated food products. Genotyping of sero-
type O157:H7 by PFGE is frequently used to trace sources or
settings of community outbreaks, and to link isolates from
human cases of bloody diarrhoea to isolates from implicated
food products [92]. Can ExPEC strains spread similarly and
cause outbreaks? Like enteric E. coli pathogens, ExPEC strains
also colonize the intestine before they cause diseases such as
UTI and BSI. They enter the intestine via the oral route.
Genotyping by ERIC2-PCR and PFGE unmasked a cluster of
a clonal ExPEC lineage causing uncomplicated, commu-
nity-acquired UTI that came to be genotyped as ST69 in a
California university campus in the late 1990s [54]. These
women had no healthcare contact prior to their episode of
UTI. Other clusters of clonal lineages, such as ST131, ST95,
ST393, and ST73, isolated from community-acquired UTIs as
well as from community-onset BSIs demonstrate that, indeed,
outbreaks of ExPEC do occur, and that a large proportion of
the increase or change in prevalence of these lineages in a
setting may be explained by epidemiological spread, rather
than local selection by antimicrobial drugs. These observations
have led to the suggestion that these lineages may be spread in
contaminated food products. Several reports have described
the isolation of clonal ExPEC strains from non-human sources,
including food products, food animals, and companion and wild
animals (Table 3); isolation from household person-to-person
transmissions has also been reported [39,77,93–106]. How-
ever, large community or geographically widespread outbreaks
of orally transmitted enteric bacterial pathogens by companion
or person-to-person transmission do not occur, and these two
modes of transmission therefore cannot explain the global
geographical distribution of the pandemic ExPEC lineages.
It should be pointed out, however, that pulsotypes of
ExPEC isolates from food or food animal sources that match
100% to those of human isolates are rare. An analysis of 495
E. coli isolates from animal and environmental sources col-
lected in the USA between 1965 and 2002 identiﬁed several
ST69 (CgA) strains, but only one, isolated from a cow, showed
94% similarity by PFGE to a human UTI CgA isolate from
California [97]. Another study of 579 ST131 isolates from
1967 to 2009 found that, among 170 pulsotypes, there was
little pulsotype commonality between human and food or food
animal isolates [107]. This is not surprising, as these studies
compared E. coli isolates from human and non-human sources
from different geographical sites and time periods. PFGE is
used to detect clonal dissemination or transmission that
occurs over a short period of time. Unless the human isolates
are analysed prospectively and concurrently with isolates from
locally consumed food products, an exact PFGE match is
difﬁcult to demonstrate. Such studies, although not yet
common, do show a closer match of pulsotypes of human
and food isolates [96]. Therefore, the role of food products as
a potential vehicle for the spread of clonal lineages of ExPEC
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cannot be ruled out at present. The practice of administering
low-dose antibiotics as growth promoters in food animal
husbandry may be a major driver of the selection and
establishment of reservoirs of such drug-resistant ExPEC
lineages (Fig. 1).
Summary
Undoubtedly, communities and healthcare institutions will
continue to observe the emergence and ﬂuctuation in time of
epidemic-prone ExPEC lineages. The pandemic potential of
ExPEC strains appears to involve both biological and epidemi-
ological factors that facilitate increased transmission. One
major concern is the evolution of drug resistance in these
clonal strains. ST393 strains have been clearly shown to have
gained increased resistance since their ﬁrst identiﬁcation in the
late 1980s in Europe [25]. ST131 strains are progressively
gaining new resistance phenotypes, including those that
express KPC-2 carbapenemase and NDM-1 metallo-b-lactam-
ase [108–112]. Furthermore, the genes encoding these drug
resistance determinants are found in high-risk clonal lineages
of Gram-negative bacterial pathogens other than E. coli [113].
It is unclear what can be done to prevent this evolution of drug
resistance among pandemic strains. More research is clearly
needed to understand the epidemiology and biology of the
pandemicity of ExPEC organisms.
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